American Conference Institute (ACI) will be holding its 8th Annual Paragraph IV Disputes conference on April 28-29, 2014 in New York, NY. The conference will offer presentations on the following topics:
• On the 30th Anniversary of the Drug Price Competition and Patent Term Restoration Act:
Understanding Hatch-Waxman's Transformative Impact on the Pharmaceutical Industry
• Assessing Pharmaceutical Patent Sustainability and Vulnerability: Strategies and Considerations for Brand Names and Generics in Anticipating, Identifying and Determining Which Patents Will Be Ripe for Challenges of Invalidity and Non-Infringement
• Use of IPR and Other PTO Proceedings in a Paragraph IV Challenge: Strategies for Brand Names and Generics in Navigating PTO Proceedings in ANDA Litigation
• The Gauntlet Rethrown: The Paragraph IV Certification and Notice Letter
• Of Prior Art and Double Patenting: Exploring the Dichotomy between the Federal Circuit and PTO on Obvious Findings and the Potential Impact of the Goodlatte Bill on Double-Patenting Type Obviousness
• Let the Games Begin: Advanced Strategies for Drafting and Perfecting Pleadings and Effectively Using Dispositive Motions in Paragraph IV Disputes
• Working With Local Counsel and within Local Rules: Magistrate and Local Counsel Roundtable
• A View from the Bench
• Claim Construction and Markman Hearings: Standards, Jurisprudential Splits and Strategies for Paragraph IV Litigation
• FTC Keynote: Reverse Payment Settlements and Other Antitrust Concerns Impacting Paragraph IV Litigation in the Wake of Actavis -- to be presented by Markus H. Meier, Assistant Director, Health Care Division, Bureau of Competition, Federal Trade Commission
• Perils of the Safe Harbor: Understanding How the Resetting of the Boundaries of 271 (e)(1) In the Aftermath of Classen and Momenta is Impacting Paragraph IV Litigation Strategies
• In the Limelight: Strategies and Theories of Inducement, Contributory and Divided Infringement in Paragraph IV Litigation Concerning Method of Treatment Patents
• Assessing GDUFA Implementation and Additional Regulatory Developments at FDA Which Impact Paragraph IV Litigation
• Looking Beyond 180 Days: New Exclusivity Challenges for Brand Names and Generics and Related Implications for Paragraph IV Challenges
• A Pros and Cons Analysis of Launching At Risk and Survey of New Developments in Seeking Injunctive Relief and Damages
• Ethical Considerations for Paragraph IV Matters before the PTO and District Courts: Inequitable Conduct and More
In addition, a post-conference workshop, entitled "The Master Class on Settling Paragraph IV Disputes: Drafting and Negotiating Strategies for Brand-Names and Generics -- A Hands-On, Practical Approach in the Aftermath of Actavis" will be offered from 9:00 am to 4:00 pm on April 30, 2014.
The agenda for the Paragraph IV Disputes conference can be found here. More information regarding the workshop can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration fee for the conference is $2,295 (conference alone), $3,110 (conference and workshop), or $1,395 (workshop alone). Those registering by March 14, 2014 will receive a $300 discount for the conference or a $220 discount for the conference and workshop. Those registering by April 11, 2014 will receive a $200 discount for the conference or a $120 discount for the conference and workshop. Those interested in registering for the conference can do so here, by e-mailing [email protected], by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Patent Docs is a media partner of the Paragraph IV Disputes conference.
Comments